- Home
- VOR vs APLT Comparison
VOR vs APLT Comparison
Compare VOR & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- APLT
- Stock Information
- Founded
- VOR 2015
- APLT 2016
- Country
- VOR United States
- APLT United States
- Employees
- VOR N/A
- APLT N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- APLT Health Care
- Exchange
- VOR Nasdaq
- APLT Nasdaq
- Market Cap
- VOR 207.1M
- APLT 178.6M
- IPO Year
- VOR 2021
- APLT 2019
- Fundamental
- Price
- VOR $18.94
- APLT $0.84
- Analyst Decision
- VOR Buy
- APLT Buy
- Analyst Count
- VOR 6
- APLT 5
- Target Price
- VOR $84.00
- APLT $4.13
- AVG Volume (30 Days)
- VOR 392.4K
- APLT 2.6M
- Earning Date
- VOR 11-07-2025
- APLT 11-10-2025
- Dividend Yield
- VOR N/A
- APLT N/A
- EPS Growth
- VOR N/A
- APLT N/A
- EPS
- VOR N/A
- APLT N/A
- Revenue
- VOR N/A
- APLT $121,000.00
- Revenue This Year
- VOR N/A
- APLT N/A
- Revenue Next Year
- VOR N/A
- APLT $5,935.35
- P/E Ratio
- VOR N/A
- APLT N/A
- Revenue Growth
- VOR N/A
- APLT N/A
- 52 Week Low
- VOR $2.62
- APLT $0.30
- 52 Week High
- VOR $65.80
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- VOR 34.54
- APLT 38.81
- Support Level
- VOR $19.62
- APLT $0.75
- Resistance Level
- VOR $26.76
- APLT $1.24
- Average True Range (ATR)
- VOR 2.09
- APLT 0.14
- MACD
- VOR -1.28
- APLT -0.08
- Stochastic Oscillator
- VOR 9.23
- APLT 10.43
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.